Literature DB >> 25091681

Rotavirus gastroenteritis in India, 2011-2013: revised estimates of disease burden and potential impact of vaccines.

Jacob John1, Rajiv Sarkar1, Jayaprakash Muliyil1, Nita Bhandari2, Maharaj K Bhan3, Gagandeep Kang4.   

Abstract

While improvements in oral rehydration use and access to healthcare have contributed to impressive gains in child survival, diarrheal diseases remain the second most important cause of child mortality in India. Pathogen specific disease rates, while key to deciding on the utility of specific public health interventions such as vaccines, are extremely difficult to obtain in developing country settings with less than optimal health access, diagnostic services and information systems. This study combined disease burden within five cohorts of infants followed up for diarrheal morbidity with data from the nationally representative Indian Rotavirus Surveillance Network and applies rates of rotavirus related events to UNICEF birth and mortality estimates for India. These estimates, while limited by the lack of data from nationally representative population based studies, use methods consistent with those employed by the World Health Organization Child Health Epidemiology Reference Group. We estimate that 11.37 million episodes of rotavirus gastroenteritis occur each year in India, requiring 3.27 million outpatient visits and 872,000 inpatient admissions when health access is unconstrained, resulting in a need for Rs. 10.37 billion each year in direct costs. An estimated 78,000 rotavirus-associated deaths occur annually of which 59,000 occur in the first 2 years of life. Introduction of a rotavirus vaccine of similar efficacy to the Rotavac in the national immunization program would result in 686,277 fewer outpatient visits, 291,756 fewer hospitalizations and 26,985 fewer deaths each year in India, assuming no indirect effects for the vaccine.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25091681     DOI: 10.1016/j.vaccine.2014.03.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Prevalence of rotavirus, norovirus and enterovirus in diarrheal diseases in Himachal Pradesh, India.

Authors:  Swapnil Jain; Nutan Thakur; Neelam Grover; Jitendraa Vashistt; Harish Changotra
Journal:  Virusdisease       Date:  2016-02-03

2.  Glucose enhances rotavirus enterotoxin-induced intestinal chloride secretion.

Authors:  Liangjie Yin; Rejeesh Menon; Reshu Gupta; Lauren Vaught; Paul Okunieff; Sadasivan Vidyasagar
Journal:  Pflugers Arch       Date:  2017-05-10       Impact factor: 3.657

3.  Economic impact of thermostable vaccines.

Authors:  Bruce Y Lee; Patrick T Wedlock; Leila A Haidari; Kate Elder; Julien Potet; Rachel Manring; Diana L Connor; Marie L Spiker; Kimberly Bonner; Arjun Rangarajan; Delphine Hunyh; Shawn T Brown
Journal:  Vaccine       Date:  2017-04-25       Impact factor: 3.641

4.  Genotypic determination of human group A rotaviruses from Goa and Meghalaya states, India.

Authors:  Abhay Raorane; Zunjar Dubal; Sandeep Ghatak; Michael Mawlong; B Susngi; Virendra Gaonkar; Eknath Chakurkar; Sukhadeo Barbuddhe
Journal:  Heliyon       Date:  2020-08-19

5.  Molecular Analysis of VP7 Gene of Rotavirus G1 Strains Isolated from North India.

Authors:  Swapnil Jain; Jitendraa Vashistt; Kanika Gupta; Ashok Kumar; Harish Changotra
Journal:  Curr Microbiol       Date:  2016-08-26       Impact factor: 2.188

6.  Evidence-Based Health Behavior Interventions for Cholera: Lessons from an Outbreak Investigation in India.

Authors:  Avinash Deoshatwar; Dawal Salve; Varanasi Gopalkrishna; Anuj Kumar; Uday Barve; Madhuri Joshi; Savita Katendra; Varsha Dhembre; Shradha Maheshwari; Rajlakshmi Viswanathan
Journal:  Am J Trop Med Hyg       Date:  2021-10-25       Impact factor: 3.707

7.  Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.

Authors:  Johnie Rose; Laura Homa; Sharon B Meropol; Sara M Debanne; Roger Bielefeld; Claudia Hoyen; Mendel E Singer
Journal:  PLoS One       Date:  2017-11-03       Impact factor: 3.240

8.  Impact of maternal antibodies and infant gut microbiota on the immunogenicity of rotavirus vaccines in African, Indian and European infants: protocol for a prospective cohort study.

Authors:  Kuladaipalayam Natarajan C Sindhu; Nigel Cunliffe; Matthew Peak; Mark Turner; Alistair Darby; Nicholas Grassly; Melita Gordon; Queen Dube; Sudhir Babji; Ira Praharaj; Valsan Verghese; Miren Iturriza-Gómara; Gagandeep Kang
Journal:  BMJ Open       Date:  2017-03-29       Impact factor: 2.692

9.  A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.

Authors:  Prasad S Kulkarni; Sajjad Desai; Tushar Tewari; Anand Kawade; Nidhi Goyal; Bishan Swarup Garg; Dinesh Kumar; Suman Kanungo; Veena Kamat; Gagandeep Kang; Ashish Bavdekar; Sudhir Babji; Sanjay Juvekar; Byomkesh Manna; Shanta Dutta; Rama Angurana; Deepika Dewan; Abhijeet Dharmadhikari; Jagdish K Zade; Rajeev M Dhere; Alan Fix; Maureen Power; Vidyasagar Uprety; Varsha Parulekar; Iksung Cho; Temsunaro R Chandola; Vikash K Kedia; Abhishek Raut; Jorge Flores
Journal:  Vaccine       Date:  2017-09-26       Impact factor: 3.641

10.  Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years.

Authors:  Christopher Troeger; Ibrahim A Khalil; Puja C Rao; Shujin Cao; Brigette F Blacker; Tahmeed Ahmed; George Armah; Julie E Bines; Thomas G Brewer; Danny V Colombara; Gagandeep Kang; Beth D Kirkpatrick; Carl D Kirkwood; Jason M Mwenda; Umesh D Parashar; William A Petri; Mark S Riddle; A Duncan Steele; Robert L Thompson; Judd L Walson; John W Sanders; Ali H Mokdad; Christopher J L Murray; Simon I Hay; Robert C Reiner
Journal:  JAMA Pediatr       Date:  2018-10-01       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.